Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping Its Interaction with the Methyltransferase PRC2
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The histone methyltransferase PRC2 plays a central role in genomic stability and cellular development. Consequently, its misregulation has been implicated in several cancers. Recent work has shown that a histone H3 mutant, where the PRC2 substrate residue Lys27 is replaced by methionine, is also associated with cancer phenotypes and functions as an inhibitor of PRC2. Here we investigate the mechanism of this PRC2 inhibition through kinetic studies and photo-cross-linking. Efficient inhibition is dependent on (1) hydrophobic lysine isosteres blocking the active site, (2) proximal residues, and (3) the H3 tail forming extensive contacts with the EZH2 subunit of PRC2. We further show that naturally occurring post-translational modifications of the same H3 tail, both proximal and distal to K27M, can greatly diminish the inhibition of PRC2. These results suggest that this potent gain of function mutation may be “detoxified” by modulating alternate chromatin modification pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our previous work indicates that the presence of several histone posttranslational modifications in the H3 tail, both proximal and distal to K27, was able to neutralize the toxic effect of the K27M mutation (5).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Self-citationThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Lowary, P. T., & Widom, J. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1494 · Cited by 1,778
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury III, W. J., Voigt, P., Martin, S. R., Taylor, W. R., De Marco, V., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,196
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 855
Research works printed but not linked: 2
- Wu G.; Broniscer A.; McEachron T. A.; Lu C.; Paugh B. S.; Becksfort J.; Qu C.; Ding L.; Huether R.; Parker M.; et al. St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project. Nat. Genet. 2012, 44, 251.22286216
- Copeland R. A. Reversible Inhibitors. In Enzymes; John Wiley & Sons, Inc.: Hoboken, NJ, 2002; pp 266– 304.
Cited by
Items 101–123 of 123
Update in Pediatric Neuro-Oncology
Khatua, S., & Pillay Smiley, N. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-540-3 · Cited by 1
The spread of chemical biology into chromatin
Hegazi, E., & Muir, T. W. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107776 · Cited by 1
Self-citationRomero, P. (2021) · theses.fr (ABES) · doi:10.70675/9543ced6z1413z4989z83cfz64e346d81eb7 · Cited by 1
Lee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2376-1 · Cited by 1
Paine, D., & Paine, D. (2023) · UA Campus Repository (The University of Arizona) · Cited by 1
Lipodepsipeptide Antibiotics: Total Synthesis and Mechanism of Action Studies Using 19F-NMR
Kralt, B. (2020) · UWSpace (University of Waterloo) · Cited by 1
Spatio-temporal organisation of histone variants : from nucleosomes to nuclei
Karagyozova, T. (2023) · theses.fr (ABES) · doi:10.70675/9bc458efze7cbz44d3zb793z581bbc0e800c
A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma
Zhu, J., Tsoli, M., Bertoldo, J. B., Mueller, S., & Ziegler, D. S. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf008
Role of histone variant H3.3 mutations in the development of pediatric high-grade glioma
Vidal, A. (2019) · theses.fr (ABES) · doi:10.70675/0a0b10b2z384bz4620z9925z7b056c7f8f83
Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma
Groves, A., Kirkland, O. O., Cascio, C. L., Wang, X., Heaslip, C., Marques, J. G., Song, C., Poetschke, R., Wang, T., Chin, D. H., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag142
Faculty Opinions recommendation of Regulation of histone methylation by automethylation of PRC2.
Harrington, L. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736562386.793567832
Gordon, J., & McGinty, R. K. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102802
Prognostic Indicators and Treatment Strategies for Diffuse Midline Glioma: a Systematic ReviewPreprint
Fiorino, M., Kostick, N., Baughn, C., Bolufer, A., Iwai, T., Alkassis, F. F., & Scherer, A. G. (2021) · Research Square · doi:10.21203/rs.3.rs-947806/v1
Lewis, N., Klein, R. H., Kelly, C., Yee, J., & Knoepfler, P. S. (2022) · Figshare · doi:10.6084/m9.figshare.19801953
Functional Characterization of Breast Cancer–Associated Histone Mutations
Edwards, A. D., Dai, Y., Singh, S., Thornton, M. A., Nandu, T. S., Kittler, R., Camacho, C. V., Huang, D., & Kraus, W. L. (2026) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0982
Mendez, F. (2020) · Deep Blue (University of Michigan)
N-terminal modification of Histone H3 inhibits H3K27M-mediated loss of H3K27 trimethylationPreprint
Poux, N., Boyle, G. E., Zhang, D. F., Caplan, J., Kebede, A. F., Sethaudom, A., Gainey, I., Famous, O. E., Sarthy, J. F., & Bandopadhayay, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634760
Towards the creation of synthetic Escherichia coli via Tryptophan and Methionine substitutions
Tolle, I. (2021) · DepositOnce · doi:10.14279/depositonce-12049
Establishing an In-vivo Model of Low-grade Glioma
Yanchus, C. (2022) · TSpace (University of Toronto)
Metadata
- Authors
- Brown, Z. Z., Müller, M. M., Jain, S. U., Allis, C. D., Lewis, P. W., & Muir, T. W.
- Affiliations
- Princeton University (US)
- Princeton University , , , ,
- University of Wisconsin–Madison (US)
- Rockefeller University (US)
- Corresponding author
- Muir, Tom W.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-09-02
- Volume
- 136
- Issue
- 39
- Pages
- 13498-13501
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC4183613
- OpenAlex
- W2314376783
- Cited by
- 111
- References
- 19
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 9 · 2019: 18 · 2018: 11 · 2017: 13 · 2016: 7 · 2015: 5 · 2014: 1
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of the American Chemical Society (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- National Institute of General Medical Sciences (R01 GM107047, R37-GM086868)
- STARR foundation (I6-A614)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- H3K27M mutation, polycomb repressive complex 2, EZH2, histone methyltransferase inhibition, cancer, protein-protein interaction, photocrosslinking, enzyme kinetics, chromatin modification, gain-of-function mutations
- MeSH terms
- Enzyme Inhibitors, HeLa Cells, Histones, Humans, Kinetics, Models, Molecular, Mutation, Neoplasms, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.